The Company will evaluate the efficacy and safety of BI 425809 in the CONNEX trial program, which includes the phase 3 CONNEX-1 (ClinicalTrials.gov: NCT04846868), CONNEX-2 (ClinicalTrials.gov ...

Enhancing glutamate function by stimulating the glycine site of the NMDA receptor with glycine, D-serine, or with drugs that inhibit glycine reuptake may have therapeutic potential in schizophrenia.

A novel glycine transporter inhibitor improved cognition after 12 weeks among individuals with schizophrenia, according to results of a double-blind, randomized, placebo-controlled phase 2 study ...

Glycine transporter GlyT1 is the main regulator of neurotransmitter glycine levels in the brain, and also important for e.g. blood cells, where glycine is required for the synthesis of heme.

Determination of glycine transporter opens new avenues in development of psychiatric drugs. ScienceDaily . Retrieved April 7, 2025 from www.sciencedaily.com / releases / 2021 / 03 / 210304112506.htm ...

Glycine can stimulate or inhibit neurons in the brain, thereby controlling complex functions. Unraveling the three-dimensional structure of the glycine transporter, researchers have now come a big ...

Glyzin und GABA sind die beiden wichtigsten hemmenden Botenstoffe im zentralen Nervensystem. Störungen der hemmenden Erregungsübertragung konnten bereits mit neurologischen Erkrankungen wie Epilepsie ...

Boehringer Ingelheim’s schizophrenia hopeful hit the mark in a phase 2 study, ... The treatment, BI 425809, inhibits a protein called glycine transporter type 1, or Gly-T1.

Glycine transporter 1 (GlyT1), a glycine transporter protein, is highly co-localized with the NMDA receptor. Inhibition of GlyT1 can increase the concentration of glycine in the synaptic cleft, ...